摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-Chloro-3-fluorophenoxy)piperidine | 367501-02-8

中文名称
——
中文别名
——
英文名称
4-(4-Chloro-3-fluorophenoxy)piperidine
英文别名
——
4-(4-Chloro-3-fluorophenoxy)piperidine化学式
CAS
367501-02-8
化学式
C11H13ClFNO
mdl
——
分子量
229.68
InChiKey
FKKIMHRWJDGOEQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    21.3
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • [EN] ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN<br/>[FR] DÉRIVÉS D'ARYLCARBOXAMIDE EN TANT QU'INHIBITEURS DE CANAL SODIQUE POUR LE TRAITEMENT DE LA DOULEUR
    申请人:AMGEN INC
    公开号:WO2011103196A1
    公开(公告)日:2011-08-25
    The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    本发明提供了一种抑制电压门控钠通道(Nav)的化合物,特别是Nav 1.7,因此适用于治疗通过抑制这些通道可治疗的疾病,特别是慢性疼痛疾病。还提供了含有这种化合物的药物组合物以及制备这种化合物的方法。
  • Chemical compounds
    申请人:Rigby Aaron
    公开号:US20050171092A1
    公开(公告)日:2005-08-04
    The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    本发明提供了一个式子(I)的化合物:其中变量在此定义;以及制备这种化合物的过程;以及在治疗趋化因子(例如CCR3)或H1介导的疾病状态中使用这种化合物的用途。
  • SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES
    申请人:TAKEDA PHARMACEUTICAL COMPANY LIMITED
    公开号:US20150111922A1
    公开(公告)日:2015-04-23
    The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof: (I) in which m, n, W, X, Y, Z, R 1 , R 2 , R 3 and R 4 are as defined in the specification, for use in the treatment or prevention of a diseases o conition mediated by a prokineticin, such as psychiatric and neurological conditions.
    本发明提供了公式(I)的化合物及其药学上可接受的盐:(I)其中m、n、W、X、Y、Z、R1、R2、R3和R4如规范中所定义,用于治疗或预防由前动力素介导的疾病或情况,例如精神和神经疾病。
  • CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS
    申请人:Bregman Howard
    公开号:US20130131035A1
    公开(公告)日:2013-05-23
    The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    本发明提供了一种抑制电压门控钠通道(Nav)的化合物,特别是Nav 1.7,因此可用于治疗可通过抑制这些通道治疗的疾病,特别是慢性疼痛疾病。还提供了含有这种化合物的药物组合物以及制备这种化合物的方法。
  • Substituted bipiperidine intermediates and derivatives thereof
    申请人:AstraZeneca AB
    公开号:EP1493743A1
    公开(公告)日:2005-01-05
    A compound of formula (Xllla): wherein: L2 is hydrogen, tert-butoxycarbonyl or benzyl; t is 0 or 1; m and p are, independently, 0, 1 or 2; X is CH2, C(O), O, S, S(O), S(O)2 or NR37; provided that when m and p are both 1 then X is not CH2; and R1 has specified values.
    一种式(Xllla)化合物: 其中L2 是氢、叔丁氧基羰基或苄基;t 是 0 或 1;m 和 p 分别是 0、1 或 2;X 是 CH2、C(O)、O、S、S(O)、S(O)2 或 NR37;但当 m 和 p 均为 1 时,X 不是 CH2;R1 具有指定值。
查看更多